News | August 29, 2025
Sai Life Sciences completes Phase II of production block 11 at Bidar
With the addition of Phase II (~91 KL) in Q1 FY26, the combined capacity of the block now stands at ~200 KL
With the addition of Phase II (~91 KL) in Q1 FY26, the combined capacity of the block now stands at ~200 KL
The CRDMO segment contributed Rs. 452.7 crore, recording a robust 70.5 per cent YoY increase
NJ Bio is currently executing a major new program for an existing innovator customer with multiple ADC candidates in their pipeline
Dr. Venkatraman brings over 25 years of experience in small molecule and Biologics drug development, manufacturing, and advancing strategic growth initiatives
The site, spanning approximately 25,000 square meters, is expected to commence operations by the end of 2025
The trial targets MCAS/MCAD, an under-recognized, debilitating condition with an unknown cause and no cure
PAT stood at Rs. 88 crore for Q4 FY25 as compared to Rs. 56 crore in Q4FY24, an increase of 57%
The foray into this new segment will help Vimta to enter into the growing CDMO business of biologics and peptides
The partnership provides Sai Life Sciences with a greenhouse gas emissions reduction of up to 90% for its international logistics needs by using SAF
Asahi Kasei Life Science covers a broad range of bioprocess products and services
Subscribe To Our Newsletter & Stay Updated
